Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNRNASDAQ:CDNANASDAQ:GTHNASDAQ:RDNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$3.88-1.9%$5.95$2.62▼$8.99$39.70M0.6714,643 shs3,997 shsCDNACareDx$17.07-1.8%$21.00$7.42▼$34.84$950.56M2.17845,682 shs376,609 shsGTHGenetron$4.03+0.2%$3.98$2.08▼$4.05$127.43M0.5151,662 shs412,600 shsRDNTRadNet$48.11-2.8%$56.62$45.82▼$93.65$3.59B1.85636,626 shs495,028 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech-7.49%-15.96%-24.33%-43.97%-48.62%CDNACareDx-5.55%-5.34%-14.43%-22.21%+73.01%GTHGenetron0.00%0.00%0.00%0.00%0.00%RDNTRadNet-5.71%-2.29%-4.48%-30.76%+3.06%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNRBurning Rock BiotechN/AN/AN/AN/AN/AN/AN/AN/ACDNACareDx3.1749 of 5 stars3.31.00.04.22.40.00.6GTHGenetronN/AN/AN/AN/AN/AN/AN/AN/ARDNTRadNet3.8905 of 5 stars3.71.00.04.63.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 0.00N/AN/AN/ACDNACareDx 2.57Moderate Buy$31.8386.53% UpsideGTHGenetron 0.00N/AN/AN/ARDNTRadNet 3.40Buy$73.2552.26% UpsideCurrent Analyst Ratings BreakdownLatest CDNA, GTH, BNR, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025RDNTRadNetBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $60.003/5/2025RDNTRadNetRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$85.00 ➝ $65.003/3/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$26.00 ➝ $25.002/27/2025CDNACareDxStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.001/22/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$94.00 ➝ $88.001/22/2025RDNTRadNetBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$85.00 ➝ $74.001/15/2025CDNACareDxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$28.00 ➝ $24.001/15/2025RDNTRadNetJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$100.00 ➝ $80.001/14/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$26.00 ➝ $26.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$515.82M0.08N/AN/A$10.56 per share0.37CDNACareDx$333.79M2.83N/AN/A$4.83 per share3.53GTHGenetron$94.34M1.35N/AN/A$2.63 per share1.53RDNTRadNet$1.83B1.95$2.56 per share18.81$11.79 per share4.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$92.07M-$1.88N/A∞N/A-83.50%-60.68%-42.30%N/ACDNACareDx-$190.28M$1.02N/AN/AN/A-45.90%-53.70%-30.42%5/8/2025 (Estimated)GTHGenetron-$117.21MN/A0.00∞N/AN/AN/AN/AN/ARDNTRadNet$3.04M$0.03N/A90.77N/A-0.25%4.29%1.45%5/6/2025 (Estimated)Latest CDNA, GTH, BNR, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2025Q4 2024BNRBurning Rock Biotech-$1.3970-$1.08+$0.3170-$1.08N/A$17.27 million2/27/2025Q4 2024RDNTRadNet$0.21$0.22+$0.01$0.07$459.42 million$477.10 million2/26/2025Q4 2024CDNACareDx$0.05$1.51+$1.46$1.51$84.56 million$86.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/AGTHGenetronN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A3.042.78CDNACareDxN/A4.103.87GTHGenetronN/AN/AN/ARDNTRadNet0.892.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%CDNACareDxN/AGTHGenetron10.74%RDNTRadNet77.90%Insider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%CDNACareDx4.90%GTHGenetronN/ARDNTRadNet5.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.24 million7.14 millionNot OptionableCDNACareDx74055.43 million51.01 millionOptionableGTHGenetron99331.62 millionN/ANot OptionableRDNTRadNet8,97074.04 million70.24 millionOptionableCDNA, GTH, BNR, and RDNT HeadlinesRecent News About These CompaniesB. Metzler seel. Sohn & Co. AG Makes New Investment in RadNet, Inc. (NASDAQ:RDNT)April 4 at 4:50 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Shares Sold by American Century Companies Inc.April 3 at 3:34 AM | marketbeat.comClearbridge Investments LLC Acquires 207,582 Shares of RadNet, Inc. (NASDAQ:RDNT)April 2 at 5:08 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Given Consensus Recommendation of "Buy" by BrokeragesApril 2 at 4:21 AM | marketbeat.comPrudential Financial Inc. Sells 14,722 Shares of RadNet, Inc. (NASDAQ:RDNT)April 2 at 3:57 AM | marketbeat.comVanguard Group Inc. Grows Stock Holdings in RadNet, Inc. (NASDAQ:RDNT)April 2 at 3:57 AM | marketbeat.com13,100 Shares in RadNet, Inc. (NASDAQ:RDNT) Acquired by KLP Kapitalforvaltning ASApril 2 at 3:49 AM | marketbeat.comRadNet, Inc. (NASDAQ:RDNT) Shares Acquired by Axiom Investors LLC DEApril 1 at 6:12 AM | marketbeat.comSei Investments Co. Purchases 16,643 Shares of RadNet, Inc. (NASDAQ:RDNT)March 29, 2025 | marketbeat.comLoomis Sayles & Co. L P Has $58.30 Million Holdings in RadNet, Inc. (NASDAQ:RDNT)March 28, 2025 | marketbeat.comRobotti Robert Reduces Stock Position in RadNet, Inc. (NASDAQ:RDNT)March 28, 2025 | marketbeat.comA Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The PackMarch 27, 2025 | msn.comRadNet (RDNT): Buy, Sell, or Hold Post Q4 Earnings?March 27, 2025 | msn.comWhat 5 Analyst Ratings Have To Say About RadNetMarch 26, 2025 | nasdaq.comBarclays Lowers RadNet (NASDAQ:RDNT) Price Target to $60.00March 25, 2025 | marketbeat.comBarclays Issues Pessimistic Forecast for RadNet (NASDAQ:RDNT) Stock PriceMarch 25, 2025 | americanbankingnews.comRadNet price target lowered to $60 from $74 at BarclaysMarch 25, 2025 | markets.businessinsider.comRadnet (RDNT) Receives a Buy from BarclaysMarch 25, 2025 | markets.businessinsider.comRadnet (RDNT) Receives a Buy from BarclaysMarch 25, 2025 | markets.businessinsider.com6RDNT : What 5 Analyst Ratings Have To Say About RadNetMarch 24, 2025 | benzinga.comEmerald Advisers LLC Has $45.90 Million Stock Holdings in RadNet, Inc. (NASDAQ:RDNT)March 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockJoby Aviation: From Prototype to ProfitabilityBy Jeffrey Neal Johnson | March 11, 2025View Joby Aviation: From Prototype to ProfitabilityMicrosoft’s Big Malaysia Bet Could Pay Off for InvestorsBy Chris Markoch | March 28, 2025View Microsoft’s Big Malaysia Bet Could Pay Off for InvestorsFedEx Delivers Another Crushing Blow to Its Stock PriceBy Thomas Hughes | March 21, 2025View FedEx Delivers Another Crushing Blow to Its Stock PriceTop Utility Stocks Powering Through VolatilityBy Ryan Hasson | March 25, 2025View Top Utility Stocks Powering Through VolatilityCDNA, GTH, BNR, and RDNT Company DescriptionsBurning Rock Biotech NASDAQ:BNR$3.88 -0.08 (-1.90%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.CareDx NASDAQ:CDNA$17.07 -0.30 (-1.75%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Genetron NASDAQ:GTHGenetron Holdings Limited, a precision oncology platform company, focuses on cancer management by utilizing technologies in molecular biology and data science in the People's Republic of China. It offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. The company also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. Genetron Holdings Limited was founded in 2013 and is headquartered in Beijing, the People's Republic of China.RadNet NASDAQ:RDNT$48.11 -1.40 (-2.83%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
